The aims of the present study were to examine whether periovulatory administration of a cyclooxygenase (COX)-2 inhibitor affects human ovulation and endocrine parameters. METHODS: Thirteen healthy women, 30-40 years of age, without hormonal treatment and with regular menstrual cycles (27-34 days), were given the selective COX-2 inhibitor rofecoxib (n ⍧ 6) or placebo (n ⍧ 7) in a random double-blind fashion. In an initial control cycle, serial hormonal analyses, detection of a measurable mid-cycle urine LH peak and transvaginal ultrasound scans were performed to confirm normal ovulatory and endocrinological cyclic patterns, in all participating women. During the subsequent treatment cycle, serial ultrasound scans were performed. When the dominant follicle reached 14-16 mm in diameter, 25 mg rofecoxib or placebo was taken orally, once daily for 9 consecutive days, during which follicle size was monitored daily by ultrasound scans and serial hormone analyses were performed. RESULTS: Four of the six women who received rofecoxib demonstrated delayed follicle rupture, >48 h after the LH peak, when compared with the placebo group, who all had follicular rupture >36 h after the detected LH peak. No differences in peripheral serum concentrations of progesterone, oestradiol, LH and FSH were observed between placebo and rofecoxib groups, when analysed at specified time intervals. CONCLUSIONS: This study suggests that selective COX-2 inhibition has a negative, local effect on human ovulation, resulting in delayed follicular rupture, without affecting peripheral hormonal cyclicity.
Introduction
COX-2 has been demonstrated to be expressed in granulosalutein cells isolated from women undergoing IVF (Narko In the preovulatory follicle of mammalian species, the LH et al., 1997) . surge induces gene expression of a large number of proteins Non-steroidal anti-inflammatory drugs (NSAIDs) in women (Richards, 1994) resulting in changes in concentrations of with different autoimmune diseases exert non-selective COX many ovulatory mediators within the follicle, including prostainhibition resulting in ovulatory failure (Akil et al., 1996; glandins (PGs) , subsequently leading to follicle wall rupture. Smith et al., 1996) . Daily consumption of 150-200 mg In humans, several studies have shown that PGs are important indomethacin (Killick and Elstein, 1987; Akil et al., 1996) ovulatory mediators (Smith et al., 1986; Killick and Elstein, during the periovulatory period resulted in 100% ovulation 1987); however, the precise mechanisms of action on ovulation inhibition, which was seen as luteinized unruptured follicle are still unclear. Effects on follicular blood flow (Kranzfelder (LUF), a condition with delayed and abnormal follicular et al., 1992) and collagen degradation (Reich et al., 1991) rupture. Indomethacin affects several different intra-ovarian have been suggested. mediators apart from PGs, such as calcium, kallikrein and The enzyme catalysing the rate-limiting step in PG synthesis 15-hydroxyeicosatetranoic acid methyl esters (HETEs) exists in two isoforms, cyclo-oxygenase (COX)-1 and COX-2 (Northover, 1977; Tanaka et al., 1991; ) (Kujubu et al., 1991 Wong and Richards, 1991; Xie et al., and therefore the results from the latter studies may not solely 1991; O'Banion et al., 1992) . COX-1 is normally constitutively be due to PG inhibition. expressed and COX-2 is generally inducible in response to
The introduction of new selective COX-2 inhibitors in inflammatory stimuli or in response to LH in the rat ovary clinical practice has made it possible to study the importance (Richards, 1994) . COX-2 knockout mice demonstrate normal and mechanisms of action of PGs more specifically. The follicle development but are infertile due to multiple purpose of this study was to examine possible effects of the reproductive failures including defect ovulation, fertilization, selective COX-2 inhibitor, rofecoxib (RX), on ovulation in a group of healthy women with regular menstrual patterns. implantation and decidualization (Lim et al., 1997) . In humans,
Materials and methods

Subjects
Nineteen healthy women with no prior history of gynaecological or reproductive disorders volunteered for the study. None of the women were using hormonal contraception or any other medication for at least 2 months prior to the study and all had a history of regular menstrual cycles (27-34 days). All subjects gave informed consent and the study was approved by Göteborg University Human Ethics Committee and the Swedish medical products agency.
Six women were excluded from the study due either to the control cycles being Ͼ35 days or to an inability to identify a readily visible dominant follicle, up to cycle day 16, during the control or treatment cycles.
Thirteen women were included in the study. In the placebo group, one woman was para 3, two were para 2, one was para 1 and three were para 0. In the treatment group, four women were para 2, one was para 1 and one was para 0. Figure 1 . Mean follicle diameter of dominant follicle in treatment This prospective, double-blind, randomized RX-placebo study was cycle in relation to day of LH peak (LH peak ϭ day 0) measured performed at the Department of Obstetrics and Gynaecology at by transvaginal ultrasound scans (n ϭ 7 in placebo group, n ϭ 6 in Sahlgrenska University Hospital (Göteborg, Sweden). Each woman COX-2 inhibitor group). Data are means ϩ SEM. Day 1 after LH was monitored for 2-4 consecutive menstrual cycles. Cycle 1 was peak: n ϭ 6 (placebo n ϭ 1, COX-2 inhib n ϭ 5), day 2: n ϭ 4 the control cycle; cycle 2 was the treatment cycle (RX or placebo);
Experimental design
(COX-2 inhib only), day 3: n ϭ 3 (COX-2 inhib), day 4: n ϭ 2 (C@OX-2 inhib) and day 6-10: n ϭ 1 (COX-2 inhib). cycles 3 and 4 were follow-up cycles in certain cases. Menstrual cycle day 1 (CD 1) corresponded to the first day of the bleeding period.
During cycle 1, blood samples for LH, FSH, oestradiol and Progesterone, oestradiol, LH and FSH were analysed by time-resolved progesterone measurement were taken every 3-4 days. Ultrasonic fluoro-immunoassay (DELFIA; Wallac Oy, Turku, Finland). Interscans were performed with a 5 MHz transvaginal transducer. All and intra-assay coefficients of variation (CVs) for progesterone and scans were performed by two of the authors (M.P. and B.E.F.) and oestradiol were Ͻ10.1% and for LH and FSH Ͻ3.9%. each subject was examined by one investigator. All subjects were examined with ultrasound scans, beginning on CD 8, to confirm the Statistics presence of a dominant follicle (14-16 mm) after which Urine ClearUltrasound and endocrinological results during the treatment cycle, Plan ® (Unipath Ltd, Bedford, UK) was used daily, in the morning, in the placebo and RX groups, were compared, within defined time to verify the mid-cycle peak. Only women with a demonstrable intervals, relative to the highest detectable LH values (defined as ovulatory pattern, in concordance with predefined inclusion paraday 0). To find out whether there were any intra-individual differences meters, were treated with RX or placebo in a second cycle which in the hormonal patterns between the initial control and the subsequent followed immediately. treatment cycles, four clearly identifiable parameters were compared During the treatment cycle, blood samples were taken initially for each women; the highest progesterone value in respective cycle, every 3-4 days. Beginning at CD 8-10, transvaginal scans were the highest FSH value in respective cycle, the highest oestradiol value performed daily until a dominant follicle (14-16 mm) was visible.
when progesterone concentration was Ͻ5 nmol/l and the first acquired The women were then randomly and double-blindly allotted placebo FSH value in each cycle. or RX (Vioxx ® produced by Merck, Sharp and Dohme B.V., Haarlem,
The data are presented as means Ϯ SEM. Serum sample duplicates The Netherlands) 25 mg once daily for 9 consecutive days. The were analysed and the mean of the two values was used for further investigators were not aware of which substance the participants analysis. Statistical analyses were performed using analysis of variance received until all treatment cycles were completed. During the 9 (ANOVA), followed by Fisher's Exact Least Square Differences treatment days, the women were monitored daily with transvaginal (LSD) tests. Grouping factors were defined as treatment and day of ultrasound scans (24-30 h between scans), serum hormone analysis cycle in relation to the LH peak (repeated measures). The software and Clear-Plan ® urine test (until evidence of LH peak).
used for all analyses was Stat View 5.0 (Abacus Concepts, Berkeley, Follicle rupture was pre-defined as a decrease in mean follicular CA, USA). For all statistical results reported, the critical P-value was diameter of at least 3 mm (Coetsier and Dhont, 1996) and appearance set to 0.05. of intrafollicular echos. Delayed follicle rupture was defined as the absence of visible rupture within 48 h of the LH peak, measured in Results serum, but also confirmed with the Clear Plan ® urine test. Follicle rupture was pre-defined as a decrease in mean follicular diameter of
Ultrasound examinations
at least 3 mm (Coetsier and Dhont, 1996) . Women with abnormal
The dominant follicles were detected between CD 7-12 and findings during the treatment cycle were monitored in subsequent follicle diameters increased consistently and linearly in both cycles until resumption of normal ovulatory pattern was seen.
the placebo and treatment groups until the day of the LH peak (Figure 1) .
Assays
In the placebo group, the mean maximum follicle diameter All hormone samples from the treatment cycles were analysed after completion of the study. All analyses were performed in duplicates.
was 21 mm (range 19-24 mm) and the slightly ellipsoid Figure 4 . Mean day of menstrual cycle when LH peak was peak for placebo and COX-2 inhibitor groups (n ϭ 7 for placebo detected in treatment cycle as measured by LH in serum and LH group, n ϭ 6 for COX-2 inhibitor group). Data are presented as urine dip sticks (n ϭ 7 in placebo group, n ϭ 6 in COX-2 inhibitor mean ϩ SEM. P Ͻ 0.02 for placebo versus COX-2 inhibitor group). Data are presented as mean ϩ SEM. groups.
preovulatory follicles demonstrated a considerable size (P Ͻ 0.03). Two subjects in the RX group had follicular rupture 36-48 h after the LH peak and were therefore classified decrease, became more irregular in shape and intrafollicular echoes typical of luteinization appeared Ͻ36 h after the LH as having normal ovulatory patterns. The maximum mean follicle size of the four women who demonstrated delayed peak was detected (Figure 2 ). In the treatment group, the maximum mean follicle size, prior to rupture, was 30 Ϯ 4.3 follicular rupture was 34 mm (range 27-50 mm) and the follicular size decrease was delayed and occurred at CD LH mm (range 20-50 mm). The mean day of follicular rupture ( Figure 3) , but not the day of the LH peak (Figure 4 ), differed ϩ3, ϩ4, ϩ9 and ϩ10 respectively. One of these women developed a cystic structure with maximum diameter of 50 significantly between the placebo and RX groups. Follicular rupture, in the placebo group, was seen within 36 h of the LH mm on CD LH ϩ10 (Figure 2 ). This cystic structure collapsed during the periovulatory phase during cycle 3. The subject peak while mean rupture day in the RX group was day 4 Figure 5 . Mean serum concentrations of progesterone (a), oestradiol (b), FSH (c) and LH (d) in treatment cycle in relation to day of LH peak (LH peak ϭ day 0) for placebo and COX-2 inhibitor groups (n ϭ 7 in placebo group, n ϭ 6 in COX-2 inhibitor group). Data are presented as means Ϯ SEM. experienced intense abdominal pain at this time and the ( Figure 5 ), or in oestradiol rise in the follicular phase (data not shown), was seen. The regularity of the subsequent collapsed cyst was visible until CD 7 of cycle 4. This case was omitted in statistical analyses concerning follicle diameter menstrual cycle (cycle 3) was unchanged in all women. and rupture. No other side-effects were experienced in either placebo or RX groups.
Discussion Endocrinological parameters and bleeding patterns
The present study examined the effects of a novel specific COX-2 inhibitor, RX, on ovulation in a group of healthy The mean LH peak day was CD 14 for both placebo and RX groups (Figure 4) .
women. This inhibitor, RX, exerts anti-inflammatory, antipyretic and analgesic effects but with lower levels of gastroNo differences in progesterone, oestradiol, FSH and LH serum concentrations were observed between the placebo and intestinal (GI) side effects as compared with non-specific COX inhibitors (Hawkey et al., 2000) . Rofecoxib was administered RX groups ( Figure 5 ). No significant differences in the analysed intra-individual hormone parameters were seen. Thus, no delay in a double-blind fashion, thereby eliminating possible subject and investigator bias. We demonstrated a delay in ovulation in decreased progesterone concentration during the luteal phase (Ͼ48 h) in four out of six subjects in the RX group and two as studies of women taking this type of medication, on a longterm basis, demonstrate signs of normal ovulation within one out of six ovulated 36-48 h after the LH surge and classified as having normal ovulatory patterns. All women in placebo menstrual cycle after medication interruption (Akil et al., 1996; Smith et al., 1996) . Women using Norplant ® implants (Alvarez group ovulated within 36 h of the LH surge. No effect on peripheral sex steroid or gonadotrophin concentrations et al., 1996 ), RU 486 (Kekkonen et al., 1996 and a combination of RU 486 and medroxyprogesterone actetate (Croxatto et al., was seen. In this type of study, in the human female, it is critical to use 1996) have also demonstrated LUF-like disturbances.
In common with an earlier study (Killick and Elstein, 1987) , acceptable methods when monitoring follicular development. Invasive methods such as laparoscopy have been used to we examined a group of women with no prior history of infertility or any other somatic illness. In the present study, a monitor changes in the ovulatory cycle (Marik and Hulka, 1978) . The dominant follicle is first discernible by transvaginal moderate dose (25 mg/day) of the specific COX-2 inhibitor (RX) was used. Contrary to Killick and Elstein (Killick and ultrasound after CD 6 and there seems to be no difference in dominant follicle growth rate and appearance between Elstein, 1987), we used no artificial ovulatory stimulus and hormone levels in serum were followed regularly during the imminent ovulatory and non-ovulatory cycles prior to expected ovulation (Gore et al., 1995) . Daily ultrasound examinations entire study; daily during the treatment period. Despite the delay in follicular rupture, no alterations in serum progesterone together with serial hormonal analyses, however, are required in order to minimize misinterpretations of follicle development concentrations were demonstrated. Rofecoxib has demonstrated similar mechanisms of inhibiduring the periovulatory period (Petsos et al., 1985) . The mean time from the LH surge onset to follicle rupture has been tion as another selective COX-2 inhibitor, NS-398, in vitro (Ouellet and Percival, 1995; Chan et al., 1998) . We have demonstrated to be 38 Ϯ 4 h in normal cycling women (Fritz et al., 1992) , which is why delayed follicular rupture was recently demonstrated that NS-398 reduced ovulation frequency in vivo and in vitro in the rat (Mikuni et al., 1998) . A defined as the absence of rupture within 48 h, in the present study.
dose-dependent decrease in PGE 2 synthesis was seen in vivo but the ovulation rate was only affected by the highest dose Earlier studies have examined the effects of non-selective PG synthesis inhibition, affecting both COX-1 and COX-2, tested. This suggested that prostanoids must be reduced below a certain threshold level in order to inhibit ovulation. It is using traditional NSAIDs on human ovulation (Killick and Elstein, 1987) . The two COX enzymes are located in different possible that there may exist a dose-dependent response to PG inhibition, also in humans. A complete ovulation inhibition by intracellular areas and use different pools of arachidonate in distinct metabolic pathways (Morita et al., 1995) . Non-steroidal 150-200 mg indomethacin daily, in women with no prior history of gynaecological problems, has previously been menanti-inflammatory drugs assert their non-specific inhibition with varying potency and selectivity (Cryer and Feldman, tioned (Killick and Elstein, 1987; Akil et al., 1996) . A case report has described ovulatory delay with subsequent 1998). Pervading characteristics of the influence of PG synthesis inhibition on ovulation include evidence of ovulation conception following administration of 50 mg indomethacin daily (Nargund and Cheng, 1996) . It is possible that there may without conception capability and LUF, a clinical phenomenon involving ovulatory failure despite a preceding LH peak, rise be dose-dependent effects of specific COX inhibitors as well and that a dose increase of RX could possibly result in in luteal phase progesterone and secretory endometrium. The definition and prevalence of LUF, as well as luteal phase a higher incidence of delayed ovulation or possible LUF/ conception inhibition. follow-up in earlier studies, have varied (Zaidi et al., 1995; Smith et al., 1996) . Varying effects on luteal progesterone
In this study, we found no measurable difference in oestradiol, progesterone, LH or FSH profiles between the RX and concentrations have been reported (Hamilton et al., 1985; Killick and Elstein, 1987; Scheenjes et al., 1990) . LUF has placebo groups or between the initial control and treatment cycles. This is in line with our earlier study using NS-398, in been described in spontaneous menstrual cycles (Killick and Elstein, 1987; Kugu et al., 1991) but infertile women demona rat model, where no effect on ovarian production of progesterone or oestradiol was seen, suggesting that inhibition of the strate a higher incidence of LUF as compared with fertile women (Summaria et al., 1998) . Varying effects on luteal inducible PG pathway is enough to cause inhibition of ovulation in spite of undisturbed steroidogenesis. In previous studies progesterone concentrations have been reported (Hamilton et al., 1985; Killick and Elstein, 1987; Scheenjes et al., 1990) .
with non-selective PG inhibitors in humans, hormonal changes such as decreases in progesterone (Killick and Elstein, 1987) The effect of the non-selective PG synthesis inhibitor indomethacin, when administered concomitantly with HCG as and oestradiol (Hamilton et al., 1985) have been reported. It cannot be excluded that changes seen in hormone patterns an ovulatory stimulus, was investigated (Killick and Elstein, 1987 ) and a 10.7% spontaneous LUF rate was found in the during PG inhibition, with indomethacin for example, may be due to the higher dosage used or due to effects on other control group. The indomethacin treatment group demonstrated 100% LUF and a decrease in early luteal phase serum factors, which subsequently affect the hormone production from the preovulatory follicle. progesterone. Reports on women taking continuous NSAIDs, such as diclofenac, have described infertility and a high
The results of the present study demonstrate a prolongation of the time from onset of the LH surge until follicular rupture, prevalence of LUF, some with subovulatory progesterone values in the mid-luteal phase (Smith et al., 1996) . The evident by transvaginal ultrasound, by the COX-2 inhibitor RX. This indicates that the process of ovulation can proceed negative effects of NSAIDs on ovulation appear to be reversible
